Souhaitez-vous accéder aux communiqués récents ?

Combined company to operate as Obsidian Therapeutics, Inc. and to advance Obsidian’s pipeline of novel engineered TIL cell therapies for the treatment of patients with solid tumors.Obsidian’s lead...

BGB Group appoints Julie Yoon Chief Client Officer to strengthen client engagement & deliver breakthrough thinking across the commercialization lifecycle.

Exousia Pro, OTCPK: MAJI, announces the commencement of the first critical phase in bringing its revolutionary cancer screening test to the global market.

PONTE VEDRA, Fla., March 31, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and...

BEIJING, March 25, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the annual...

OXFORD, United Kingdom, March 18, 2026 (GLOBE NEWSWIRE) -- Refeyn, pemaju terkemuka teknologi mass photometry , mengumumkan pelancaran MyMass™ mass photometer (MyMassMP), sebuah instrumen kompak...

英国オックスフォード発, March 18, 2026 (GLOBE NEWSWIRE) -- 先駆的なマスフォトメトリー技術を開発するレフェイン (Refeyn) は、重要な研究課題である「サンプルは、さらなる分析に十分な品質か？」という問いに答えるために設計されたコンパクト装置である、マイマス (MyMass™) マスフォトメトリー装置 (マイマスMP (MyMassMP))...

OXFORD, Inggris Raya, March 18, 2026 (GLOBE NEWSWIRE) -- Refeyn, pengembang teknologi fotometri massa perintis, mengumumkan peluncuran MyMass™ mass photometer (MyMassMP), instrumen ringkas yang...

OXFORD, Royaume-Uni, 18 mars 2026 (GLOBE NEWSWIRE) -- Refeyn, acteur pionnier du développement de technologies de photométrie de masse, annonce le lancement de MyMass™ (MyMassMP), un photomètre de...

Refeyn launches MyMass™ — an all-in-one mass photometer for fast, accurate sample quality assessment ahead of costly structural biology workflows.